Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
February 17 2015 - 7:00AM
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company
that is developing novel cancer immunotherapies based on
tumor-infiltrating lymphocytes (TIL), today announced that its
board of directors has appointed Ryan Maynard to serve as a
director and chair of the audit committee. His appointment is
effective immediately.
Since 2010, Mr. Maynard has served as executive vice president
and chief financial officer of Rigel Pharmaceuticals, Inc.
(Nasdaq:RIGL), where he previously held several senior financial
positions since 2001. Prior to joining Rigel, Mr. Maynard served as
corporate controller and director of finance and accounting for
Personify, Inc., and controller of General Magic, Inc. He has also
held various positions at Siliconix, Inc., most recently as senior
finance manager. Earlier in his career, Mr. Maynard worked at Ernst
& Young, LLP, where he became a certified public accountant. He
holds a B.S. in accounting from Santa Clara University.
"We are delighted to welcome Ryan to Lion's board as a director
and audit committee chairman," said Elma Hawkins, President &
CEO. "Ryan has a wealth of experience in corporate financial
management and reporting, as well as an impressive track record in
fundraising for public companies. We are confident that his
insights and expertise will prove a valuable asset to the
company."
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T
cells and engineered T cells for the treatment of various cancers.
The company's lead product candidate, LN-144, is a ready-to-infuse,
autologous T-cell therapy utilizing tumor-infiltrating lymphocytes
(TIL) for the treatment of patients with metastatic melanoma, and
is based on a clinical Cooperative Research and Development
Agreement with the National Cancer Institute. TIL therapy is also
being evaluated in physician-sponsored clinical trials at MD
Anderson Cancer Center and the H. Lee Moffitt Cancer Center &
Research Institute. For more information, please
visit http://www.lionbio.com.
CONTACT: Investor Relations
The Trout Group
Tricia Truehart
646-378-2953
ttruehart@troutgroup.com
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rigel Pharmaceuticals (NASDAQ:RIGL)
Historical Stock Chart
From Apr 2023 to Apr 2024